Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 21 - 40 ( 277 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Patient Enrollment and Dosing Underway in Phase 2b Wet AMD Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE New Drug Application Accepted in Australia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b ODYSSEY Trial Commences Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Ph2b CLS-AX/wAMD Trial to Open for Enrollment in Q2:23,Readout in Q3:24; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Trial Design in Wet AMD Detailed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Gaining Clarity on FDA''s Expectations for wAMD Trials; Ph2b in Q2:23; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
TKI Validation Strengthens CLS-AX Advantage; Ph2b Start in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
6mo OASIS Extension Data Supports Durability & Safety of CLS-AX; Ph2b in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Positive Six-Month Data in Wet AMD Reported; Reiterate Buy; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Full OASIS and Interim Extension Study Results Show Durability; Ph2 in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Ph1/2a OASIS Cohort 3 & 4 Data in Nov; Takeaways from Wedbush Fireside Chat
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
OASIS Wet AMD Trial Completes Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y